Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS) announced that its Pipette clean baby care brand will expand to over 600 Target stores across North America starting in March 2021. Since its 2019 launch, Pipette has seen significant growth, particularly among Millennial parents, with year-to-date retail sales trending over 8 times higher than the same period in 2020. Pipette products are known for being 100% nontoxic and EWG verified. This retail expansion builds on existing e-commerce momentum and solidifies Pipette's position in the sustainable personal care market.
Amyris announced promising preliminary data on its RNA COVID-19 vaccine platform, developed in collaboration with IDRI. This technology shows significant antibody production against the COVID-19 spike protein and is set to enter phase 1 clinical trials. The platform could address manufacturing and distribution challenges, including storage at refrigerator and room temperatures, improving accessibility in low-resource areas. Amyris is pursuing U.S. government funding to scale production and enhance its sustainable ingredient offerings.
Amyris, Inc. (Nasdaq: AMRS) will report its fourth quarter and full year 2020 financial results on March 2, 2021, before market opening. The release will be followed by a conference call at 6:00 am PT. CEO John Melo, CFO Han Kieftenbeld, and COO Eduardo Alvarez will discuss the financial results and business updates. Amyris focuses on sustainable ingredients for Clean Health and Beauty markets and owns three consumer brands: Biossance, Pipette, and Purecane. More information can be found on their website.
Amyris, Inc. (Nasdaq: AMRS) successfully conducted its second webinar in the virtual investor mini-series themed "Delivering on the Promise of Synthetic Biology" on February 9, 2021. The event attracted over 600 attendees, featuring insights from key executives including CEO John Melo and CFO Han Kieftenbeld. Highlights included updates on strategic transactions, the beauty market, and planned product launches in 2021, with a focus on expansion in China. A replay of the webinar is available on Amyris's investor relations website.
Amyris, a leader in synthetic biotechnology, announced its second webinar in the virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology". Scheduled for February 9, 2021, at 1:00 PM ET, this session focuses on The Science Delivering Clean and Sustainable Consumer Products, featuring a business update and Q&A. This format allows for targeted engagement on specific investor topics, with a third session following later in Q2 2021. The live event can be accessed via Amyris's investor relations site.
Amyris, Inc. (Nasdaq: AMRS) announced significant results from an early clinical study of its clean topical acne formulation made from fermentation-based ingredients. Conducted by Princeton Consumer Research, the study showed Amyris's formulation performed better than 10 standard acne treatments in terms of efficacy and speed of acne reduction. The global acne treatment market is valued at $11 billion, with increasing demand due to conditions like 'maskne'. Amyris aims to finalize this formulation for consumer launch, potentially positioning itself as a leader in the clean beauty market.
Amyris, Inc. (Nasdaq: AMRS) announced on January 22, 2021, the launch of its Terasana brand, which will offer clean beauty products made from sustainably sourced natural cannabinoids. This move expands Amyris's clean beauty portfolio beyond existing brands like Biossance and Pipette. The company leverages its proprietary Lab-to-Market synthetic biology platform to create effective skincare solutions using CBG (cannabigerol) derived from sugarcane. Early clinical results indicate that these CBG formulations outperform standard CBD products for various skin conditions, positioning Amyris favorably in the cannabinoid market.
Amyris, Inc. (Nasdaq: AMRS) has been recognized as one of the top global organizations for social and environmental impact, ranked #23 out of 150 by Real Leaders in their 2021 Impact Awards. This achievement is attributed to Amyris's rapid revenue growth, which doubled from 2017 to 2019, showcasing its potential in sustainable products. The company is expanding its consumer brands, including new haircare offerings and entering the Greater China market. The awards ceremony will take place on January 27, 2021.
Amyris, Inc. (Nasdaq: AMRS) announced a new partnership with Jonathan Van Ness to launch a clean haircare brand, aiming to revolutionize the industry with sustainable, effective products. Expected to launch in summer 2021, the brand will utilize Amyris's proprietary hemi-squalane ingredient for enhanced hair health across all textures. This move expands Amyris's footprint in the clean beauty market, which represents a significant segment of the $300 billion beauty industry, furthering its commitment to inclusivity and environmentally friendly products.
Amyris, Inc. (Nasdaq: AMRS) announced its entry into the Greater China market with its Biossance Clean Beauty brand, partnering with SuperOrdinary Group. This collaboration positions Biossance within one of the fastest-growing beauty markets where consumers prioritize sustainable products. The partnership aims to leverage SuperOrdinary's expertise in establishing leading brands in China. Amyris expects significant growth, citing strong fourth-quarter sales and aiming for sales revenue equivalent to all of 2019. This strategic move aligns with the increasing demand for clean beauty products in China.
